$Atomera.US is a small-cap semiconductor materials company with a market cap of approximately $245 million. It is not a nuclear energy stock (a misreading due to the similar name), and it has no relation to SMR nuclear reactors. What it does: It develops a silicon-based restructuring material called MST and sells licenses to chip foundries and IDMs. It does not manufacture chips or equipment; it purely sells patents. The licensing fee model has extremely high gross margins, but it takes 3-5 years from customer evaluation to mass production, resulting in weak cash flow in the early stages. Benefiting sectors: Mature process reshoring to the US (driven by the CHIPS Act for 28nm+ fabs) Power semiconductors (new direction of GaN-on-Si, just advanced to the PowerAmerica proposal stage in February) Next-generation GAA transistors (disclosed in February that MST achieved manufacturability breakthrough on GAA) Three things you must know in the last 2 months: FY2025 Annual Report (2/12): Full-year revenue $65,000 (you read that right), net loss $20.2M, cash $19.2M GaN-on-Si proposal advancement (February): The step before securing PowerAmerica funding eligibility, of significant strategic importance $25M share placement (February): Issued at $5 per share, extending the runway but diluting shareholders Trading tips: Small market cap, poor liquidity, single position should not exceed 3% of the portfolio Daily fluctuations of ±5-10% are normal; single-day anomalies like +61% have also occurred Option liquidity is weak; it is recommended to only do ATM naked Calls or Protective Puts, and avoid spread structures Highest priority catalysts: Official licensing contract announcement / Final approval of PowerAmerica IIP Any news of "refinancing" or "customer loss," indiscriminate stop-loss on the day My judgment: ATOM is a typical "option payoff"—limited downside (2-year runway), open upside (revaluation once a major customer's mass production license is secured). Suitable for small satellite positions, not suitable for core positions. The risk of chasing trends is greater than patiently waiting for an opportunity.